Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM)

被引：0
|
作者：
Chen, CI
White, D
Kouroukis, CT
Stewart, AK
Howson-Jan, K
Larratt, L
Powers, J
Eisenhauer, E
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] QE II Hlth Sci Ctr, Halifax, NS, Canada
[3] Margaret & Charles Juravinski Canc Ctr, Hamilton, ON, Canada
[4] London Hlth Sci Ctr, London, ON, Canada
[5] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada
[6] Natl Canc Inst, Clin Trials Grp, Kingston, ON, Canada
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3288
引用
下载
收藏
页码：896A / 896A
页数：1
相关论文
共 50 条
  • [31] Activity of fludarabine (FAMP) in heavily previously treated waldenstrom's macroglobulinemia (WM): A report of 74 cases.
    Binet, JL
    BLOOD, 1996, 88 (10) : 1914 - 1914
  • [32] Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
    Chen, Christine I.
    Kouroukis, C. Tom
    White, Darrell
    Voralia, Michael
    Stadtmauer, Edward
    Stewart, A. Keith
    Wright, John J.
    Powers, Jean
    Walsh, Wendy
    Eisenhauer, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) : 1570 - 1575
  • [33] Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia
    Treon, Steven P.
    Meid, Kirsten
    Gustine, Joshua
    Patterson, Christopher J.
    Matous, Jeffrey V.
    Ghobrial, Irene M.
    Castillo, Jorge J.
    BLOOD, 2015, 126 (23)
  • [34] Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenstrom macroglobulinemia
    Castillo, Jorge J.
    Libby, Edward N.
    Ansell, Stephen M.
    Palomba, M. Lia
    Meid, Kirsten
    Flynn, Catherine A.
    Leventoff, Carly
    Hergott, Christopher B.
    Sewastianik, Tomasz
    Morgan, Elizabeth A.
    Carrasco, Ruben
    Fromm, Jonathan R.
    Yang, Guang
    Hunter, Zachary
    Treon, Steven P.
    BLOOD ADVANCES, 2020, 4 (20) : 5089 - 5092
  • [35] A phase I study of bortezomib (PS-341) in pediatric patients with relapsed or refractory leukemia: A Children's Oncology Group study.
    Horton, T. M.
    Thompson, P. A.
    Bomgaars, L. R.
    Adamson, P. C.
    Krailo, M.
    Ingle, A.
    Blaney, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 507S - 507S
  • [36] A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenstrom Macroglobulinemia
    Ghobrial, Irene M.
    Moreau, Philippe
    Harris, Brianna
    Poon, Tiffany
    Jourdan, Eric
    Maisonneuve, Herve
    Benhadji, Karim A.
    Hossain, Anwar M.
    Nguyen, Tuan S.
    Wooldridge, James E.
    Leblond, Veronique
    CLINICAL CANCER RESEARCH, 2012, 18 (18) : 5043 - 5050
  • [37] A phase II multicenter randomized study of the proteasome inhibitor bortezomib (VELCADE™, formerly PS-341) in multiple myeloma (MM) patients (pts) relapsed after front-line therapy.
    Jagannath, S
    Barlogie, B
    Berenson, J
    Siegel, D
    Irwin, D
    Richardson, PG
    Alexanian, R
    Limentani, SA
    Alsina, M
    Lee, S
    Esseltine, DL
    Kauffman, M
    Adams, J
    Schenkein, DP
    Anderson, KC
    BLOOD, 2002, 100 (11) : 812A - 812A
  • [38] Genetic analysis of proteasome-related pathways in patients with advanced gastric adenocarcinomas (AGA) treated on a phase II study with PS-341 (bortezomib) with or without irinotecan.
    Ocean, AJ
    Lane, ME
    Xiang, Z
    Huang, X
    Schnoll-Sussman, F
    Holloway, SB
    Yu, B
    Wright, J
    Wadler, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 889S - 889S
  • [39] A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, Velcade™) and melphalan in patients with relapsed or refractory multiple myeloma
    Yang, HH
    Vescio, R
    Schenkein, D
    Berenson, JR
    CLINICAL LYMPHOMA, 2003, 4 (02): : 119 - 122
  • [40] Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study
    Davis, NB
    Taber, DA
    Ansari, RH
    Ryan, CW
    George, C
    Vokes, EE
    Vogelzang, NJ
    Stadler, WM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 115 - 119
12345